Anti_Mouse, pab CTLA_4 Source Rabbit
- Known as:
- Anti_Mouse, pab CTLA_4 Source Rabbit
- Catalog number:
- 103-P43
- Product Quantity:
- 100 µg
- Category:
- -
- Supplier:
- Reliatech
- Gene target:
- Anti_Mouse pab CTLA_4 Source Rabbit
Related genes to: Anti_Mouse, pab CTLA_4 Source Rabbit
- Gene:
- CTLA4 NIH gene
- Name:
- cytotoxic T-lymphocyte associated protein 4
- Previous symbol:
- CELIAC3, IDDM12
- Synonyms:
- CD152, CD, GSE, CTLA-4
- Chromosome:
- 2q33.2
- Locus Type:
- gene with protein product
- Date approved:
- 1989-05-25
- Date modifiied:
- 2019-04-23
Related products to: Anti_Mouse, pab CTLA_4 Source Rabbit
Related articles to: Anti_Mouse, pab CTLA_4 Source Rabbit
- Humoral immunity, mediated by B cells that mature in germinal centers in lymph nodes (LNs), is essential for adaptive immune responses, but its role in antitumor immunity and responses to immunotherapy remain unclear. Here, we show that activation of B cells in tumor-draining deep cervical LNs (dcLNs) is necessary for the efficacy of CTLA-4 (cytotoxic T lymphocyte-associated protein 4) immune checkpoint blockade in glioma in vivo. Anti-CTLA-4 therapy enhanced T follicular helper cell (T cell) expansion in dcLNs, leading to germinal center B cell responses, immunoglobulin G (IgG) class switching, and the generation of glioma-reactive antibodies. Glioma-bearing mice lacking antibody-secreting cells did not benefit from CTLA-4 blockade. Distally secreted IgG accumulated in the tumor microenvironment and promoted glioma cell phagocytosis in vivo. These findings define a B cell-dependent mechanism underlying CTLA-4-mediated control of glioma and provide a conceptual framework for future therapeutic strategies in tumor. - Source: PubMed
Publication date: 2026/07/10
Kim YuminKang InKang Byeong HoonPark Won HyungKim Chae WonKim Hyun-JinLa JeongwooKwon Myoung SeungPark Sang HeeIm Seo HyeonKim Hyeon CheolKu Keun BonKim MinjiOh Ji EunLee Heung Kyu - The combination of radiotherapy (RT) and immunotherapy has emerged as a central strategy in modern oncology, yet clinical outcomes remain highly variable. This variability is critically influenced by timing, including sequencing, interval, and temporal alignment with immune dynamics. We performed a systematic review to evaluate how mechanism-guided timing of RT relative to different immunotherapy classes shapes antitumor efficacy. - Source: PubMed
Publication date: 2026/07/10
Cattaneo Carlo GuglielmoPozzo EnricoPanza GiuliaChiloiro GiudittaRomano AngelaGaletto MatteoNardini MatteoPlacidi LorenzoGambacorta Maria AntoniettaBoldrini Luca - Evidence indicates that hematological indices, such as neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), and neutrophil-to-hemoglobin and lymphocyte (NHL), are valuable for assessing disease activity in rheumatoid arthritis (RA). This study investigated their potential as biomarkers for monitoring treatment response and disease improvement in RA patients receiving biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). - Source: PubMed
Jhou Jyun-PeiHou Yin-HuiChang Yu-ShengChang Jui-ChiaShen Wan-Chen - Human papillomavirus (HPV) prevalence is high among men who have sex with men (MSM), increasing the risk of anal cancer. Key risk factors include HIV co-infection and persistent HPV infection, although the underlying mechanisms remain unclear. - Source: PubMed
Publication date: 2026/06/25
Ober VeronicaGruener EvaWang DanniBaranov OlgaStirner RenateReiling GabrieleConca RaffaeleDächert ChristopherIbarra GerardoSeybold UlrichBogner Johannes RGeldmacher ChristofHeld KathrinRoider Julia - Colorectal cancer remains a major cause of cancer mortality, and most microsatellite stable tumors derive little benefit from immune checkpoint blockade. Here, we identify a microbiome-dependent mechanism that converts immune-refractory colorectal cancer into a more immunologically responsive state. Using orthotopic mouse models spanning distinct genetic and immunologic contexts, we show that a Helicobacter-containing microbiome suppresses primary tumor growth and limits metastasis. This protective state is associated with increased intratumoral lymphocyte infiltration and stronger effector programs. Mechanistically, microbial exposure induces MHC class II expression in colon cancer cells to promote anti-tumor immunity. Tumor-intrinsic loss of CIITA abrogates microbial protection, whereas enforced CIITA expression is sufficient to increase intratumoral T cell accumulation, restrict progression and metastasis, and sensitize microsatellite-stable tumors to PD-1 and CTLA-4 blockade. In human microsatellite-stable patient-derived organoids, increased cancer-cell MHC-II enhanced interactions with autologous immune cells and increased tumor cell apoptosis. Together, these findings define a microbiome-cancer cell antigen presentation axis that restrains metastasis and overcomes immunotherapy resistance in colorectal cancer. - Source: PubMed
Publication date: 2026/07/04
Chung CharlieOzcelik ElifZhang JialingShen ZeliEskiocak OnurQin YihanHabel JillOzler KadirSubhash SanthilalAminzada ZakariaDev GaganGarcia LibiaLyons Scott KHand Timothy WRivadeneira David EFox James GWestcott Peter M KRogava MeriBeyaz Semir